SPY339.28-6.50 -1.88%
DIA277.00-6.34 -2.24%
IXIC11,384.54-163.74 -1.42%

VBL Therapeutics Announces Additional New European Patent In The MOSPD2 Platform Technology

TEL AVIV, Israel, Oct. 15, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced that the European Patent Office (EPO) has granted Patent #3328401, which covers VBL’s proprietary

· 10/15/2020 07:07

TEL AVIV, Israel, Oct. 15, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced that the European Patent Office (EPO) has granted Patent #3328401, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology conditions.

VBL has identified MOSPD2 as a novel target whose expression is induced in multiple tumors, including colon, esophagus, liver and breast among others. Expression of MOSPD2 plays a role in the ability of cancer cells to metastasize. The point that MOSPD2 is expressed abundantly and specifically on tumors, but not on normal tissues, makes it a good and novel target for killing of tumor cells.

"This new patent is an important milestone achieved by VBL in securing intellectual property protection for our MOSPD2 program and for targeting MOSPD2 for anti-cancer therapy," said Erez Feige, Ph.D, MBA, VP Business Operations at VBL. Earlier this week, VBL announced the grant of another European Patent #3328408, which covers VBL’s proprietary antibodies to treat inflammatory conditions.

The claims in the granted patent cover the use of such anti-MOSPD2 antibody/antibody fragment to treat a wide range of cancers which express MOSPD2, including solid tumors and hematological cancers. The patent is expected to provide protection for VBL’s anti-MOSPD2 platform, until at least July 2036.